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CytokinesBinge alcohol drinking has emerged as a typical phenomenon in young people. This pattern of drinking,
repeatedly leading to extremely high blood and brain alcohol levels and intoxication is associated with
severe risks of neurodegeneration and cognitive damage. Mechanisms involved in excitotoxicity and neu-
roinflammation are pivotal elements in alcohol-induced neurotoxicity. Evidence has demonstrated that
PPARc receptor activation shows anti-inflammatory and neuroprotective properties. Here we examine
whether treatment with the PPARc agonist pioglitazone is beneficial in counteracting neurodegeneration,
neuroinflammation and cognitive damage produced by binge alcohol intoxication. Adult Wistar rats were
subjected to a 4-day binge intoxication procedure, which is commonly used to model excessive alcohol
consumption in humans. Across the 4-day period, pioglitazone (0, 30, 60 mg/kg) was administered orally
twice daily at 12-h intervals. Degenerative cells were detected by fluoro-jade B (FJ-B) immunostaining in
brain regions where expression of pro-inflammatory cytokines was also determined. The effects of piogli-
tazone on cognitive function were assessed in an operant reversal learning task and the Morris water
maze task. Binge alcohol exposure produced selective neuronal degeneration in the hippocampal dentate
gyrus and the adjacent entorhinal cortex. Pioglitazone reduced FJ-B positive cells in both regions and pre-
vented alcohol-induced expression of pro-inflammatory cytokines. Pioglitazone also rescued alcohol-
impaired reversal learning in the operant task and spatial learning deficits in the Morris water maze.
These findings demonstrate that activation of PPARc protects against neuronal and cognitive degenera-
tion elicited by binge alcohol exposure. The protective effect of PPARc agonist appears to be linked to
inhibition of pro-inflammatory cytokines.
 2017 Elsevier Inc. All rights reserved.1. Introduction
Chronic alcohol intoxication resulting from binge drinking
results in significant activation of neurodegenerative processes
(Vetreno and Crews, 2015; Vetreno et al., 2016). The alcoholic
brain shows reduction in brain volume and weight, enlargement
of ventricles and gray as well as white matter shrinkage in cortical
and subcortical structures (Pfefferbaum et al., 1992; Vetreno andCrews, 2015). Alcohol-induced neuropathological alterations in
brain structure and function are often correlated with impairments
in cognitive processes (Bowden and McCarter, 1993; White, 2003).
In laboratory animals, it is well established that large doses of alco-
hol (11–15 g/kg/day) administered over a short period of time
(4 days) reliably produce neurotoxicity in various corticolimbic
areas including the hippocampal dentate gyrus (DG) and the
entorhinal cortex [EC, (Collins et al., 1996; Crews et al., 2004;
Obernier et al., 2002a)]. The binge model of human alcoholic neu-
rodegeneration, which mimics a single cycle of binge intoxication
in human alcoholics (Braconi et al., 2010), is further validated by
the fact that during alcohol intoxication animals reach sustained,
high blood alcohol levels (BALs), commonly observed among alco-
holics. Furthermore, neuronal deficits in animals treated with thisagonist
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functions, such as learning and memory impairment as well as
behavioral deficits including maladaptive perseverant behavior
(Cippitelli et al., 2010a,b; Obernier et al., 2002b).
It has been proposed that alcohol-induced brain damage may
result from imbalance in expression and activation of transcription
factors that regulate anti-inflammatory /pro-survival versus pro-
inflammatory/pro-death processes (Crews and Nixon, 2009).
Indeed, both in vitro and in vivo evidence have shown that alcohol
shifts this balance toward neuroinflammation by decreasing cAMP
responsive element-binding protein (CREB)-mediated signaling
(Zou and Crews, 2006) or increasing toll-like receptor (TLR) 4 and
downstream nuclear factor jB (NF-jB) signaling (Alfonso-
Loeches et al., 2010; Crews et al., 2006; Davis and Syapin, 2004;
Fernandez-Lizarbe et al., 2013).
Peroxisome proliferator-activated receptors (PPARs) are ligand-
activated transcription factors of the nuclear hormone receptor
superfamily. They are involved in the transcriptional control of
genes regulating various physiological processes such as lipid-
homeostasis, glucose metabolism, inflammation, and cellular dif-
ferentiation and proliferation (Desvergne and Wahli, 1999). Ago-
nists of the isoform PPARc such as pioglitazone or rosiglitazone
are commonly used medications in the treatment of type II dia-
betes. Beside their effect on metabolic disorders, PPARc agonists
also modulate inflammatory responses, including immune activity
in the central nervous system (Kapadia et al., 2008). This is consis-
tent with the observation that PPARc was found in several brain
regions both in neuronal and non-neuronal cells (Moreno et al.,
2004) although a recent study indicates that PPARc is constitu-
tively expressed at higher levels in neurons than non-neuronal
cells (Warden et al., 2016). Thus, PPARcmay be an important ther-
apeutic target for neurodegenerative diseases. Accordingly, neuro-
protective potential of PPARc agonists has been demonstrated in
animal models of acute CNS insults [i.e., spinal cord injury (Park
et al., 2007)] and models of chronic CNS injuries including Alzhei-
mer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis,
and multiple sclerosis (Diab et al., 2002; Kapadia et al., 2008;
Kaundal and Sharma, 2010; Schintu et al., 2009). Efficacy of PPARc
agonists was also shown in a mouse model of fetal alcohol spec-
trum disorders (Drew et al., 2015; Kane et al., 2011).
Immune or brain pro-inflammatory signaling is not only rele-
vant for neurodegeneration. Recent evidence supports the influ-
ence of the neuroimmune system on learning and memory and
neuroplasticity (Williamson and Bilbo, 2013). Thus, actions of alco-
hol on neuroimmune function may be important for the develop-
ment of aspects of alcohol dependence such as escalation of
consumption, craving, tolerance, and withdrawal (Crews et al.,
2011; Robinson et al., 2014). PPARc agonists have been recently
shown to modulate excessive alcohol consumption, alcohol with-
drawal symptoms and stress but not cue-induced reinstatement
of alcohol seeking in rats (Stopponi et al., 2013, 2011), thus provid-
ing promising preclinical evidence for novel and effective alcohol
addiction medications.
Stemming from the initial work, which supports a role of piogli-
tazone in reducing alcohol addiction and its emerging protective
effects in various neurological dysfunctions, here we examine
whether treatment with pioglitazone is beneficial in attenuating
neurodegeneration elicited by excessive alcohol exposure. First
we characterized fluorojade B (FJ-B) immunohistochemistry in
the DG and the EC, two brain regions known to be sensitive to
alcohol-induced neurotoxicity. Subsequently, using operant rever-
sal learning and spatial orientation strategy-shift tasks, we moni-
tored the effect of PPARc activation on re-learning and cognitive
flexibility. Finally, we examined the ability of pioglitazone to mod-
ulate expression of pro-inflammatory cytokines as a possiblePlease cite this article in press as: Cippitelli, A., et al. Protection against alcoho
pioglitazone. Brain Behav. Immun. (2017), http://dx.doi.org/10.1016/j.bbi.2017mechanism for its neuroprotective actions following binge alcohol
exposure.
2. Materials and methods
2.1. Animals
Male Wistar rats (Charles River, Calco, Italy), weighing 300 to
350 g (8–10 weeks old) at the beginning of the experiments, were
pair-housed with free access to tap water and food pellets (4RF18,
Settimo Milanese, Italy) except where specified. The animals were
maintained in a temperature- and humidity-controlled vivarium
on a reverse 12-h light/dark cycle (lights off at 8:30 AM). Behav-
ioral experiments were conducted during the dark phase of the
cycle. Animals were handled three times before each experiment.
All procedures followed the EU Directive for Care and Use of Labora-
tory Animals and were approved by the Ethical Committee of the
University of Camerino, Italy.
2.2. Drugs
Pioglitazone was prepared from the pharmaceutical form Actos
(30 mg tablets, Takeda). Tablets were suspended in distilled water
to reach dosages of 30 mg/kg and 60 mg/kg. Pioglitazone was
administered orally (by gavage) in a 1 ml/kg volume. Alcohol solu-
tion (20% vol/vol) was prepared by diluting 95% alcohol with water
and made available orally.
2.3. Binge alcohol treatment
All rats used in the present study (N = 157) were subjected to a
4-day binge intoxication (or to a control) procedure in which alco-
hol (20% vol/vol) was administered orally every 8 h to reach doses
of 11–15 g/kg/day as previously described (Cippitelli et al., 2014;
Majchrowicz, 1975). Alcohol was administered in a vehicle made
up with water, 6% sucrose and 14.7% milk powder (Mellin, Milan,
Italy). Alcohol treated animals were given a priming dose of 5 g/
kg of body weight. Additional alcohol was administered every 8 h
for 4 consecutive days at 8:00 AM, 4:00 PM, and 12:00 AM based
on the animals’ estimated BAL, as determined using a six-point
intoxication scale (Majchrowicz, 1975). Control (CON) rats
received equal volumes of the vehicle. Four batches of rats were
used. One batch (N = 29) was employed for histochemical analysis
of FJ-B. These rats were assigned to two groups of 17 alcohol
exposed, in turn divided into three groups of 5–6 receiving vehicle,
pioglitazone (PIO) 30 mg/kg, or PIO 60 mg/kg twice daily at 12-h
intervals across the 4-day binge period (7:00 AM and 11:00 PM),
and 12 control exposed divided into three groups of 4 rats receiv-
ing vehicle, PIO 30 mg/kg, or PIO 60 mg/kg. A second group (N = 30;
8 non-alcohol exposed vehicle treated, 8 non-alcohol exposed trea-
ted with PIO 60 mg/kg, 7 alcohol exposed vehicle treated and 7
alcohol exposed receiving PIO 60 mg/kg) was employed for gene
expression analysis. The third (N = 53) and the fourth (N = 43)
batch of rats were divided into 4 groups as described above and
used to examine operant reversal learning and to determine BALs
and reversal learning in the Morris Water Maze (MWM), respec-
tively (Supplemental Table 1).
2.4. BALs
Twenty-four blood samples (150–200 ml) consisting of 6 non-
alcohol exposed vehicle treated, 6 non-alcohol exposed treated
with PIO 60 mg/kg, 6 alcohol exposed vehicle treated and 6 alcohol
exposed receiving PIO 60 mg/kg were taken from the rat tail vein
60 min after the last administration of the 4-day binge alcohol pro-l-induced neuronal and cognitive damage by the PPARc receptor agonist
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then immediately centrifuged (10 min, 1400g). Alcohol content
was then assayed from 5 ml plasma aliquots using an Analox instru-
ment (Lunenburg, MA). Single point calibrations from 25–400 mg%
were done for each set of samples with reagents provided by Ana-
lox (Gilpin et al., 2009; Richardson et al., 2008). Instrumentation
background determined from non-alcohol treated samples was
subtracted to calculate BAL of alcohol-treated animals.2.5. FJ-B staining
FJ-B was purchased from Histochem, Inc., (Jefferson, AR) and
used as a marker of degenerating neurons (Schmued and
Hopkins, 2000). Three hours after the last alcohol gavage, rats were
perfused with 4% paraformaldehyde under isoflurane anesthesia.
Horizontal 20-mm cryosections were obtained, allowing visualiza-
tion in the same section of both ventral hippocampi containing
the DG and the EC. Sections were mounted directly on gelatin-
coated slides and stained for FJ-B according to the manufacturer’s
protocol. Dry slides were cleared in xylene and cover-slipped with
Cytoseal (Richard-Allan Scientific, Kalamazoo, MI). For cell density
analysis an Olympus microscope (Olympus Corporation, Japan)
equipped with a Fitch filter was used. Six horizontal sections con-
taining the bilateral hippocampi and the respective EC regions
were analyzed for degenerating cells between 5.6 to 6.6 mm ven-
tral from bregma. Cell counting was conducted as previously
described (Cippitelli et al., 2010a,b; Cippitelli et al., 2014). Degen-
erating granule cells of the entire DG were measured using the pro-
gram Image J (Schneider et al., 2012). Results for EC degeneration
are depicted as counts per square mm by dividing the total number
of degenerating cells found in 48 examined microscope fields,
equivalent to 16.8 square millimeters (single field area was 0.35
square millimeters  4 fields per side  2 sides per section  6 sec-
tions per animal, for a total of 16.8 square millimeters) with a 20
microscope objective. Data for EC and DG degenerating cells are
presented as number per square millimeter.2.6. RNA isolation, cDNA synthesis and real time polymerase chain
reaction
Rats were decapitated three hours after the last alcohol gavage,
the same time point used to harvest samples for histochemical
analysis of FJ-B. Brains were quickly removed, areas of interest
were dissected and snap frozen in 40 C isopentane, and stored
at -80 C until use. RNA isolation and cDNA synthesis was executed
as previously described (Drew et al., 2015). Briefly, tissue was
homogenized using a BBX24B Bullet Blender Blue homogenizer
with 0.5 mm RNase-free beads for approximately 6 min at speed
8 (Next Advance, Averill Park, NY). RNA was isolated from tissue
homogenate using the RNeasy Lipid Tissue Mini Kit and optional
on-column DNA digestion using the supplementary RNase-free
DNase set according to the manufacturer’s instructions (Qiagen,
Valencia, CA). RNA concentration and integrity were evaluated
using an Agilent 2100 Bioanalyzer with its associated RNA 6000
Nano kit (Agilent Technologies, Santa Clara, CA). The iScriptTM cDNA
synthesis kit was used to prepare cDNA as described by the man-
ufacturer (Bio-Rad, Hercules, CA). Quantitative real-time poly-
merase chain reaction (qRT-PCR) was performed using TaqMan
primers (assays # Rn00580432m1 for IL-1b, Rn01410330m1 for
IL-6, Rn00667869 m1 for b-actin; ThermoFisher Scientific, Wal-
tham, MA) and SsoAdvancedTM Universal Probes Supermix (Bio-
Rad). Data were calculated as the mean DCt relative to the house-
keeping gene b-actin. The DDCtmethod was employed to generate
fold expression variance of ethanol and drug treated groups com-
pared to control.Please cite this article in press as: Cippitelli, A., et al. Protection against alcoho
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This procedure was conducted in operant conditioning cham-
bers (Med Associates, Inc., St. Albans, VT) enclosed in lit, sound-
attenuating and ventilated cubicles and equipped with two retract-
able levers located in the front panel, laterally (on the right and left
side) to a food pellet magazine. The pellet dispenser was positioned
behind the front panel of the chambers. Chambers were also
equipped with visual stimuli located above the levers (right and
left cue lights) and near the top of the chamber on the back panel
(house light). A microcomputer controlled the delivery of the rein-
forcer, presentation of visual stimuli and recording of the behav-
ioral data. Operant training and testing methods used are
described elsewhere (Abdul-Monim et al., 2003).
2.7.1. Training
Rats maintained at food restriction regimen (16–18 g per day)
were initially trained for 4 days to press the lever for delivery of
one 45-mg food pellet (Test Diet, 5-TUM, Richmond, IN) in 20-
min daily sessions under a fixed ratio 1 (FR-1) reinforcement
schedule using two active levers. Subsequently, rats were trained
to press either the right or the left lever for food delivery under
FR-1 for an additional 4 days. The active lever was varied from
day to day to avoid lever bias. Rats were then trained to respond
for food in presence and absence of a visual cue for 20 days. In
the former case reward contingencies were right lever-right cue
(RR) and left-lever left cue (LL), in the latter case, reward contin-
gencies were right lever-left cue (RL) or left lever-right cue (LR).
Thus, half of animals that were initially rewarded following RR or
LL schedule for 10 days (varied day to day) were switched to RL
or LR for other 10 days and the other half did the opposite. The
experimental session began with the house light being illuminated.
After 3 s, the levers, together with the stimulus cue, were pre-
sented. Following a lever press, the levers were retracted and the
house light was extinguished for a 3-s time out period. A correct
response on the active lever resulted in delivery of a food pellet
and an incorrect response resulted in no food delivery. The house
light was then turned on again and the cycle repeated. The exper-
imental session was terminated following 128 lever presses (the
total number including active and inactive lever presses) or
40 min (cut-off). At the end of this training period all rats were
subjected to the 4-day binge alcohol or control treatment in which
rats were pre-treated with PIO 60 mg/kg dose or its vehicle as
described above.
2.7.2. Testing
Following 5-day recovery from alcohol intoxication the operant
training on all reward contingencies was briefly recalled (2 ses-
sions for each randomly scheduled reward contingency). On test-
ing day, rats were first given access to the same reward
contingency of the training session used on the previous day for
a maximum period of 5 min or 25 lever presses (including both
active and inactive lever presses, initial task). Then, after 2 min
time-out signalled by the house light being turned off in which ani-
mals remained in the operant chamber, the reward contingency
was reversed so that animals rewarded in the presence of the
visual cue (RR or LL) were rewarded for responses made on the
lever not signalled by the cue (LR or RL, respectively) and vice versa
(reversal task). Similar to the initial task, the reversal task was car-
ried out for a maximum period of 5 min or following a total num-
ber of 25 lever presses including correct and incorrect responses.
2.8. MWM task
Spatial acquisition and cognitive flexibility were assessed fol-
lowing methods described previously (Cippitelli et al., 2010a;l-induced neuronal and cognitive damage by the PPARc receptor agonist
.02.001
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consisted of a circular pool (55 cm diameter) and a squared plat-
form (16 cm2) submerged below the water surface. Behavior was
recorded and analyzed using a computerized video-tracking sys-
tem (Ethovision 4, Noldus Information Technology, Wageningen,
The Netherlands). The pool was placed in a room with distal cues
represented by objects present in the text room (i.e., doors, black
rectangle drawn in a wall).
2.8.1. Reference memory
Beginning 5 days after the final gavage treatment, in which rats
were pre-treated with PIO 60 mg/kg or its vehicle and treated with
alcohol or control, acquisition of reference memory was assessed
on four daily trials over 6 days. Four random entry points were
used. If a rat did not escape to the platform within 60 s, it was
guided to the platform and allowed to remain on the platform
for 10 s. The rat was then removed and placed into a holding cage
for 50 s before the next trial, so the total intertrial interval was
60 s. The platform remained in the same location throughout the
6 days of acquisition training. Results are means of four daily trials
for latency to reach the submerged platform. Swimming speed was
an index of locomotor activity.
2.8.2. Learning of a new platform position
Following reference memory testing, which provided 6 days of
acquisition training and was 11 days after the last alcohol dose,
the platform was moved diagonally across from its initial position,
and the new learning was assessed. Each animal performed four
trials separated by 60-s intertrial intervals, starting from four ran-
dom entry points. The rest of the procedure was as described
above. Time swum to reach the new platform location, distance
to reach the new location, entries into the quadrant of the previous
platform location as well as time swum in the previous platform
location indicated learning of the new condition. For each re-
learning variable, differences between trials (‘‘savings”) served as
an index of re-learning. Swimming speed was an index of locomo-
tor activity.
2.9. Statistical analysis
Histological data from alcohol-induced neurodegeneration
were analyzed separately for DG and EC using the non-
parametric multiple independent samples Kruskal-Wallis test in
which FJ-B positive cells/mm2 was the dependent variable and
treatment groups were the independent variable. This overall anal-
ysis was followed by group comparisons using the Mann–Whitney
U test. The rate of correct responses during operant training was
analyzed by two-way mixed model ANOVA with reward contin-
gency (RR-LL vs RL-LR or treatment group) used as between-
subject and ‘‘day” as within-subject factor. Operant reversal learn-
ing data of both initial and reversal tasks were analyzed by a two-
way ANOVA using the percent of correct responses as the depen-
dent variable and ‘‘alcohol effect” and ‘‘pioglitazone treatment”
as the two independent variables. The same approach was used
for speed navigation and analysis of savings (i.e., trial 1-trial 2)
for the new learning variables (MWM task). These variables were
also analyzed to examine the effects of drug treatments across tri-
als during reversal learning by means of a two-way mixed model
ANOVA. Memory acquisition and speed navigation in the MWM
was analyzed using three-way ANOVA, where the within-subject
variable was ‘‘day” and the between-subject variables were ‘‘alco-
hol effect” and ‘‘pioglitazone treatment”. For all statistical analyses,
differences between groups were considered significant if p < 0.05.
When a statistically significant threshold was reached, ANOVA was
followed by Newman-Keuls. For gene expression analysis, interac-
tions were tested with two-way ANOVA and Tukey’s multiple com-Please cite this article in press as: Cippitelli, A., et al. Protection against alcoho
pioglitazone. Brain Behav. Immun. (2017), http://dx.doi.org/10.1016/j.bbi.2017parisons test. Grubbs test (alpha = 0.05) of expression data
identified one outlier in the non-alcohol exposed PIO treated and
alcohol exposed PIO treated groups.3. Results
3.1. Pioglitazone treatment prevents alcohol-induced
neurodegeneration in the hippocampal DG and the EC
Because very low numbers of FJ-B positive cells were present in
the groups that were not alcohol exposed, these groups had low
variance compared with groups that did receive alcohol. The anal-
ysis was therefore conducted using non-parametric approaches
(see Statistical Analysis). These analyses demonstrated an overall
significant effect of alcohol treatment in inducing neuronal cell
death in the DG (p < 0.05) as well as the EC (p < 0.05). Specifically,
the most intense damage was found in the granule cells of the DG
and the layer III pyramidal cells of the lateral EC (Supplemental
Fig. S1). In the DG, neurotoxicity was reduced by daily treatment
with pioglitazone. Pairwise comparisons showed that alcohol
exposed animals treated with the 60 mg/kg dose of pioglitazone
had significantly reduced levels of neurodegeneration as compared
to rats treated with only alcohol (p < 0.05, Fig. 1A–E). Similar to the
DG findings, treatment with 60 mg/kg of pioglitazone prevented
alcohol-induced neurotoxicity in the EC (p < 0.05, Fig. 1F–J). Piogli-
tazone 30 mg/kg did not block neurodegeneration in the DG or EC,
but a non-significant statistically reduction was observed. In areas
other than the hippocampal DG granule cells and the EC layer III
pyramidal cells, FJ-B positive cells were too few to be reliably
counted. Thus, although alcohol-induced neurotoxicity was also
observed in brain regions such as the piriform cortex, neurodegen-
eration was not quantified.
3.2. Binge treatment leads to high, sustained BALs that are not
influenced by pioglitazone
BALs were 393.1 ± 24.2 and 401.5 ± 20.0 in alcohol treated ani-
mals without or with pioglitazone treatment, respectively.
3.3. Neuroprotection by pioglitazone is associated with inhibition of
alcohol-induced increase in cytokine expression in hippocampus and
EC
Analysis of gene expression revealed 1.8-fold induction of inter-
leukin 6 (IL-6) mRNA in the hippocampus of rats treated with alco-
hol [main alcohol effect: (F(1,24) = 21.2, p < 0.001)]. This effect was
not accompanied by a main pioglitazone effect (F(1,24) = 0.8, NS)
or interaction between alcohol and pioglitazone (F(1,24) = 3.1, NS).
Administration of pioglitazone attenuated alcohol induction of IL-
6 expression in the hippocampus (Fig. 2A). Analysis of gene expres-
sion also revealed robust 2.5-fold induction of IL-6 mRNA in the EC
of rats treated with alcohol (F(1,26) = 36.1, p < 0.001). Administra-
tion of pioglitazone blocked alcohol induction of IL-6 expression
in the EC to levels observed in vehicle treated controls or treatment
with pioglitazone alone [(main pioglitazone effect (F(1,26) = 28.1,
p < 0.001); interaction ‘‘pioglitazone  alcohol” (F(1,26) = 5.4,
p < 0.05), Fig. 2B].
Interleukin 1 beta (IL-1b) mRNA expression in the hippocampus
was not significantly altered by treatment with alcohol or pioglita-
zone, or co-administration [(F(1,24) = 1.7, NS), (F(1,24) = 0.6, NS) and
(F(1,24) = 0.8, NS), respectively]. However, there was a trend to
increased IL-1b expression with alcohol treatment, and suppres-
sion of the alcohol effect by pioglitazone (Fig. 2C). In contrast, IL-
1b mRNA expression in the EC was increased 1.8-fold by alcohol
treatment (F(1,24) = 7.5, p < 0.05) and blocked by co-l-induced neuronal and cognitive damage by the PPARc receptor agonist
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Fig. 1. Binge alcohol-induced neurotoxicity in the dentate gyrus (DG) and the entorhinal cortex (EC), and its prevention by pioglitazone (0, 30, 60 mg/kg). Sections were
stained by Fluoro-Jade B (FJ-B) to visualize neurodegeneration. Panels (A), (B), (C), and (D) show representative sections (6.1 mm from bregma, 20X magnification)
visualizing labeled DG neurons in animals non-alcohol exposed treated with vehicle (PIO 0-CON), alcohol exposed treated with vehicle (PIO 0-ALC), pioglitazone 30 (PIO 30-
ALC) and 60 mg/kg (PIO 60-ALC), respectively. Panels (F), (G), (H), (I) show representative sections (6.1 mm from bregma, 20X magnification) visualizing labeled EC neurons
in PIO 0-CON, PIO 0-ALC, PIO 30-ALC and PIO 60-ALC treated rats, respectively. Panels (E) and (J) show quantification of the histological data demonstrating alcohol-induced
neurodegeneration and its prevention by pioglitazone in the DG and the EC, respectively. Data are the mean number of FJ-B positive cells/mm2 ± SEM (N = 4–6 per group).
#p < 0.05 vs. PIO 0-CON group; *p < 0.05 vs. PIO 0-ALC group. For detailed statistics, see ‘‘Results”.
Fig. 2. Effect of alcohol (ALC) and pioglitazone (PIO) on expression of interleukin 6 (IL-6) and interleukin 1b (IL-1b) genes in the hippocampus (A and C) and entorhinal cortex
(EC, B and D). Pioglitazone (60 mg/kg) blocked alcohol-induced neuroinflammation in the hippocampus and EC. Brain structures were dissected, RNA prepared, cDNA
synthesized, and mRNA levels evaluated by real-time polymerase chain reaction. b-actin expression served as normalization control. Results are expressed as fold change
relative to vehicle treated controls (PIO 0-CON). Values are mean ± SEM. N = 6–8 per treatment group. *p < 0.05, **p < 0.01, ***p < 0.001. For detailed statistics see ‘‘Results”.
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action between the alcohol and pioglitazone was detected
(F(1,24) = 1.7, NS). Pioglitazone blocked alcohol induction of IL-1b
expression to the level in vehicle treated control or treatment with
pioglitazone alone (Fig. 2D).
3.4. Pioglitazone prevents alcohol-impaired reversal learning ability in
the operant task
The sequence of the reward contingencies did not alter the cor-
rect performance of the task during training [(F(1,49) = 0.0, NS) and
(F(1,49) = 0.1, NS), Supplemental Figs. S2A and S2B, respectively].
Post-intoxication training was not altered either by alcohol, piogli-
tazone or the combined treatment [(F(3,49) = 0.6, NS), Supplemental
Fig. S3]. Also, these manipulations did not affect the performance
in the initial task [(F(1,49) = 3.1, NS), Fig. 3A]. In contrast, overall per-
formance in the reversal task was significantly modified. ANOVA
showed ‘‘alcohol effect”  ‘‘pioglitazone treatment” interaction
(F(1,49) = 5.1, p < 0.05) with pairwise comparisons showing reduced
ability of rats treated with alcohol only to perform the correct
response (p < 0.05) while pioglitazone reversed the cognitive defi-
cit induced by alcohol intoxication (p = 0.05, Fig. 3B).
3.5. Pioglitazone improves acquisition of spatial memory and prevents
alcohol-induced deficits in spatial learning in the MWM
Patterns of acquisition of spatial memory in the MWM were
modified by the treatments with both alcohol and pioglitazone
(60 mg/kg). ANOVA revealed a main effect of alcohol intoxication
(F(1,39) = 5.0, p < 0.05) accompanied by a main effect of pioglitazone
(F(1,39) = 6.0, p < 0.05) indicating that alcohol impaired reference
memory abilities while pioglitazone improved them. Interestingly,
the pioglitazone-induced enhancement of spatial memory acquisi-
tion occurred regardless of the contingent alcohol treatment, as
demonstrated by the absence of ‘‘alcohol effect”  ‘‘pioglitazone
effect” interaction. However, navigation latency to reach the hid-
den platform decreased over the 6 days of training [main time
effect: (F(5195) = 37.6, p < 0.001)] and did so in all groups, as shown
by a lack of ‘‘alcohol effect”  ‘‘pioglitazone effect”  ‘‘day” interac-
tion [(F(5195) = 0.5, NS), Fig. 4A]. Swim speed (Fig. 4B), a measure of
locomotor activity, was not altered by alcohol treatment (main
effect: F(1,39) = 0.0, NS) or pioglitazone (main effect: F(1,39) = 2.3,
NS). Speed decreased across the 6 training days (F(5195) = 16.4,
p < 0.001) in all treatment groups examined (F(5195) = 1.3, NS).
Following 6 days of acquisition trials, animals were tested for a
new spatial learning task, in which the platform was moved to the
opposite quadrant of the pool. Learning of the new platform loca-
tion differed between groups for distance traveled to reach the new
platform location (F(3,39) = 3.3, p < 0.05) and time swum to reach
this new location (F(3,39) = 4.2, p < 0.05) while the time course of
this learning was different in all variables examined [‘‘group-
”  ‘‘trial” interaction for distance traveled to reach the new plat-
form location (F(9117) = 3.3, p < 0.01), time to reach this new
location (F(9117) = 2.5, p < 0.05), entries into the original training
quadrant (F(9117) = 2.8, p < 0.01) and time swum in the original
platform quadrant [(F(9117) = 2.2, p < 0.05), Supplemental Fig. S4].
The differential course of re-learning reflected differences in
savings (improvement of performance). When analyzing savings
between trial 1 and trial 2, when most of the learning normally
occurs, savings for time spent swimming to reach the new platform
location (Fig. 4C) differed among treatments. ANOVA showed a
main effect of alcohol (F(1,39) = 5.2, p < 0.05) accompanied by a
main effect of pioglitazone (F(1,39) = 5.8, p < 0.05) and interaction
of the two factors (F(1,39) = 6.6, p < 0.05) with post hoc comparisons
indicating decreased savings of alcohol exposed rats as compared
to non-exposed controls (p < 0.01), an effect prevented by pioglitazonePlease cite this article in press as: Cippitelli, A., et al. Protection against alcoho
pioglitazone. Brain Behav. Immun. (2017), http://dx.doi.org/10.1016/j.bbi.2017(p < 0.01 vs alcohol exposed group). A similar pattern was found for
total distance swum to reach the new location (Fig. 4D; main effect
of alcohol: (F(1,39) = 3.9, p = 0.05); main effect of pioglitazone:
(F(1,39) = 11.6, p < 0.01); interaction: (F(1,39) = 7.3, p < 0.05) with post
hoc analysis showing alcohol-induced decrease in this variable
(p < 0.01) reversed by pioglitazone (p < 0.001 vs alcohol exposed
group). Savings for entries into the previously trained quadrant
(Fig. 4E) also differed [‘‘alcohol”  ‘‘pioglitazone” interaction
(F(1,39) = 4.8, p < 0.05)] with post hoc analysis showing difference
between alcohol exposed and control exposed rats (p < 0.05) as
well as prevention by pioglitazone (p < 0.05). Significant treatment
interaction was also observed for time spent swimming in the
original platform quadrant (F(1,39) = 4.1, p < 0.05, Fig. 4F). Con-
versely, swim speed did not differ between the groups during the
new learning task [main alcohol effect: (F(1,39) = 0.2, NS); main
pioglitazone effect: (F(1,39) = 0.0, NS); interaction (F(1,39) = 0.0, NS)].4. Discussion
We show here that binge-like alcohol exposure produces neu-
ronal death in the EC and hippocampal DG and that this is associ-
ated with alcohol-induced immune responses. Pioglitazone
prevents neurodegeneration and neuroinflammation. In parallel,
pioglitazone prevents alcohol-impaired re-learning performance
both in an operant task and in a spatial navigation task.
Extensive neurodegeneration was indicated by FJ-B staining in
the DG of the hippocampus and in the adjacent EC. Sparse degen-
erative neurons were detected in other areas of the brain but their
number was low compared to the DG and the EC. These findings
are consistent with previous observations indicating that binge
alcohol intoxication caused significant neuronal loss, particularly
in these regions (Cippitelli et al., 2010a; Collins et al., 1996;
Crews et al., 2004; Obernier et al., 2002a). We also found that
the PPARc agonist pioglitazone prevented in a dose dependent
manner neurotoxic consequences of the binge alcohol treatment
by suppressing the number of FJ-B positive cells in both the hip-
pocampal DG and the EC. The dose dependence of the effect sug-
gests that, in order to evaluate the potential clinical implications,
the plasma drug levels at which this response is achieved should
be compared to the levels that are achieved in humans with
FDA-approved doses. In agreement with these results, previous
studies have shown that activation of PPARc exerts a marked pro-
tective response in various models of neurodegenerative diseases
(Diab et al., 2002; Kapadia et al., 2008; Kaundal and Sharma,
2010). This effect appears to be linked to the ability of PPARc to
attenuate neuronal inflammation and to reduce activation of
inflammatory cytokines (Kapadia et al., 2008; Yi et al., 2008). Inter-
estingly, the PPARa agonist oleoylethanolamide protects against
alcohol-induced inflammatory signaling and apoptosis in the cere-
bral cortex of adolescent rats with binge drinking (Anton et al.,
2016). Here, for the first time, we provided evidence that PPARc
activation is also neuroprotective against binge alcohol drinking,
possibly through inhibition of the neuroimmune response (Drew
et al., 2015; Kane et al., 2013, 2014, 2011).
To confirm this hypothesis, we examined IL-1b and IL-6 mRNA
expression levels. These cytokines are involved in neuroinflamma-
tion initiated by excessive alcohol use (Alfonso-Loeches et al.,
2010; Crews and Nixon, 2009; Drew et al., 2015; Kane et al.,
2013, 2014). IL-1b and IL-6 are well characterized as pro-
inflammatory molecules. In addition, it should be noted that IL-6
is suggested to possess anti-inflammatory activities under some
circumstances (Schaper and Rose-John, 2015). We found that both
the DG and the EC are sensitive to neuroinflammatory processes as
dynamic changes were observed in the expression of these inflam-
matory cytokines in response to alcohol treatment. However, thesel-induced neuronal and cognitive damage by the PPARc receptor agonist
.02.001
Fig. 3. Alcohol-induced impairment of operant reversal learning and its prevention by pioglitazone. (A) Alcohol, pioglitazone (60 mg/kg) or the combined treatment did not
influence operant learning of the initial task. (B) Performance in the reversal task was reduced in alcohol exposed while pioglitazone (60 mg/kg) prevented alcohol-induced
impairment of reversal learning. Data are expressed as mean ± SEM percent (%) of correct responses (N = 53, 12–14 per group). #p < 0.05 vs control (CON) group receiving
vehicle (PIO 0-CON); *p < 0.05 vs alcohol group receiving vehicle (PIO 0-ALC). For detailed statistics, see ‘‘Results”.
Fig. 4. Reference memory and spatial learning of a new condition in the Morris water maze. (A) Acquisition of spatial memory is improved by pioglitazone and impaired by
alcohol intoxication. Data are shown as mean ± SEM latency (sec) of four daily trials across 6 days (N = 43, 10–12 per group). *p < 0.05 difference between alcohol exposed and
controls; #p < 0.05 difference between pioglitazone treated and vehicle treated groups. (B) Motor performance measured as mean of swim speed ± SEM (cm/s) was not
affected by alcohol exposure or following pretreatment with pioglitazone. Alcohol exposure induced impairment of spatial learning in the Morris water maze which was
prevented by chronic treatment with pioglitazone 60 mg/kg. Performance for the new learning is described as savings between trial 1 and trial 2 ( ± SEM, N = 43, 10–12 per
group) in (C) time swum to reach the new platform location, (D) distance swum to reach the new platform placement, (E) number of entries into the previously trained
quadrant, (F) navigation time into the original platform quadrant. *p < 0.05, **p < 0.01 alcohol vs non-exposed; #p < 0.05, ## p < 0.01, ###p < 0.001 PIO 60-ALC vs PIO 0-ALC.
For detailed statistics, see ‘‘Results”.
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was robust alcohol-induced upregulation of IL-6 and IL-1b expres-
sion in the EC that was abolished by concurrent administration ofPlease cite this article in press as: Cippitelli, A., et al. Protection against alcoho
pioglitazone. Brain Behav. Immun. (2017), http://dx.doi.org/10.1016/j.bbi.2017pioglitazone. This suggests, on the one hand, these cytokines may
contribute to alcohol-induced neurodegeneration and, on the
other, the effect of pioglitazone may be related to its ability tol-induced neuronal and cognitive damage by the PPARc receptor agonist
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mediators.
The intimate mechanisms linking PPARc function to immune
system regulation has not been fully determined yet. However, it
is known that PPARc agonists suppress the production of pro-
inflammatory molecules including cytokines and chemokines by
CNS glial cells. PPARc agonists are believed to principally suppress
inflammation by repressing the transcription of genes encoding
these pro-inflammatory molecules. This is believed to occur
through a mechanism referred to as receptor-dependent trans-
repression in which PPARc physically interacts with transcription
factors, blocking the activation of immune responsive genes
(Daynes and Jones, 2002). PPARc has been shown to act through
receptor-dependent trans-repression to suppress the activity of a
variety of transcription factors including NF-jB (Li et al., 2000).
PPARc can also alter transcription through receptor-independent
mechanisms, including suppressing specific steps in NF-jB signal-
ing pathways (Rossi et al., 2000; Straus et al., 2000). Interestingly,
alcohol has been demonstrated to activate NF-jB (Blanco and
Guerri, 2007; Ward et al., 1996). PPARc can be expressed by glia
in vivo, particularly under neuroinflammatory conditions (Diab
et al., 2002; Warden et al., 2016). Thus, PPARc suppression of
immune activity by glia may indirectly protect neurons since
pro-inflammatory molecules can be toxic to neurons. In addition,
PPARc agonists may directly alter the viability of neurons. Neurons
have previously been demonstrated to express PPARc suggesting
that pioglitazone may regulate neuron viability directly through
receptor-dependent mechanisms (Inestrosa et al., 2005). PPARc
agonists have been demonstrated to protect neurons from toxic
insults by maintaining mitochondrial function and limiting reac-
tive oxygen species formation in these cells (Fuenzalida et al.,
2007). It will be important in future studies to further define the
mechanisms by which PPARc agonists protect hippocampal and
EC neurons from the toxic effects of alcohol.
The EC and the hippocampus are closely interconnected regions
and the circuitry from the EC to the hippocampal formation is con-
sidered to be critical for memory formation and spatial learning
(Aggleton et al., 2000). Lesion studies have shown that damage of
the hippocampal area mostly produces spatial reference deficits
(Jarrard, 1993; Morris et al., 1982) whereas damage of the EC
may also compromise reversal learning abilities (Eijkenboom
et al., 2000; Hagan et al., 1992). However, cognitive impairment
resulting from binge alcohol exposure includes reversal learning
and object recognition deficits rather than deficits in acquisition
of spatial reference memory in navigation or exploration tasks in
rats (Cippitelli et al., 2010a,b; Obernier et al., 2002b). In these stud-
ies, re-learning deficits observed in binge alcohol treated animals
have been closely associated with different navigation or explora-
tory patterns reflecting increased perseverative behavior as well as
decreased cognitive flexibility. Here we tested the possibility that
the observed neuroprotective role of pioglitazone was associated
with prevention of alcohol-induced deficits in learning abilities.
This hypothesis was verified by employing two behavioral
strategy-shift tasks, both requiring intact cognitive ability and flex-
ibility, though one devoid of a spatial component (i.e., operant
reversal learning task) and the other heavily based on spatial orien-
tation (i.e., learning of a new task in the MWM). In the non-spatial
operant reversal learning task, we found a selective though weak
deficit in cued reversal learning following alcohol treatment, which
was reversed by concurrent administration of pioglitazone. These
data confirm previous evidence that excessive alcohol treatment
causes learning disabilities in non-spatial tasks (Cippitelli et al.,
2010b; Garcia-Moreno and Cimadevilla, 2012; Takahashi et al.,
2015) and demonstrate that pioglitazone ameliorates re-learning
performance in a new cue-reward contingency. The learning of a
new condition in the MWM is very sensitive to hippocampal asPlease cite this article in press as: Cippitelli, A., et al. Protection against alcoho
pioglitazone. Brain Behav. Immun. (2017), http://dx.doi.org/10.1016/j.bbi.2017well as EC damage and, therefore, cognitive consequences of alco-
hol exposure were assumed to result in a more pronounced
impairment. As expected, variables describing navigation strate-
gies of alcohol treated rats were significantly changed from the
control group. Since velocity of swimming was similar between
groups, these data indicate alcohol-induced damage of new learn-
ing performance and reduced cognitive flexibility to engage the
correct navigation strategy to reach the new platform location,
similar to what has been described previously (Cippitelli et al.,
2010a; Obernier et al., 2002b). Pioglitazone successfully prevented
this impairment. However, surprisingly, alcohol-induced cognitive
impairment was not restricted to the re-learning performance, as a
deficit in the acquisition of reference memory was also detected
following binge alcohol treatment in the present study. This find-
ing suggests that, under certain experimental conditions (i.e., dif-
ferent use of navigation cues or different experimental design),
alcohol can produce damage to the hippocampal-mediated spatial
reference memory. This evidence reconciles with previous obser-
vations obtained from lesion studies and supports the hypothesis
that alcohol-induced impairments in spatial learning and memory
parallel those induced by lesions (Matthews and Silvers, 2004).
Even more surprisingly, we also observed that pioglitazone treat-
ment was able to improve spatial reference memory for a fixed
platform location compared to non-pioglitazone treated groups.
Similarly, PPARc agonist treatment was previously associated with
improvements of hippocampal-dependent memory in mouse mod-
els for Alzheimer’s disease, indicating that PPARc agonists may act
as cognitive enhancers (Nenov et al., 2014). In addition, PPARc acti-
vation has been shown to modulate alcohol intake and preference
in two-bottle choice models of consumption but not in a limited
access binge drinking model (Blednov et al., 2015). Investigation
of potential anxiolytic or antidepressant activity of pioglitazone
(Domi et al., 2016; Kemp et al., 2014) may suggest additional
mechanisms of cognitive protection by pioglitazone following
alcohol intoxication. Further study of the therapeutic potential of
approved PPARc agonists, including pioglitazone, in alcohol-
induced neuropathology, and cognitive impairments, as well as
alcohol consumption, may provide new strategies for intervention
in alcohol use disorders.
In the present study, molecular events were assessed acutely
and behavioral effects were assessed at later time points. As
reported by Crews and Nixon (2009), neurodegeneration peaks
shortly after the last dose of alcohol in this model, the time point
that we used to measure neurodegeneration. We have previously
demonstrated that spatial memory remains impaired 10 weeks in
this alcohol model (Cippitelli et al., 2010b) and cognitive function
was tested in the present study in a two week period following
alcohol treatment. Alcohol treatment also inhibits neurogenesis,
contributing to neuron loss and perhaps cognitive impairment
(Nixon, 2006; Nixon and Crews, 2004). Given our finding that
pioglitazone protects against alcohol-induced cognitive impair-
ment, it is interesting that PPARc activation has been shown to
protect neurogenesis and cognitive function in disease models
(Ormerod et al., 2013). The protective effects of pioglitazone
appear to be long lasting as suggested by our data demonstrating
pioglitazone protection against cognitive impairments two weeks
after completion of alcohol and pioglitazone treatment.5. Conclusions
Here we show a clear protective effect by the PPARc agonist
pioglitazone against neuronal damage caused by binge alcohol
intoxication in brain regions underlying learning and memory pro-
cesses. Consistently, pioglitazone confers a wide spectrum of pro-
tection against alcohol-induced impairment of spatial and non-l-induced neuronal and cognitive damage by the PPARc receptor agonist
.02.001
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We also show that neuroinflammation importantly contributes to
alcohol-induced neurotoxicity as dynamic changes in the expres-
sion of pro-inflammatory markers were detected following alcohol
treatment. These changes were blocked by pioglitazone suggesting
that anti-inflammatory mechanisms may be responsible for the
protective effects of PPARc agonists on alcohol-induced neuronal
and cognitive damages. The present findings, together with our
previous evidence describing the ability of PPARc agonists to
reduce excessive alcohol intake and vulnerability to relapse into
alcohol seeking (Stopponi et al., 2011), provide a strong rationale
for consideration of pioglitazone or its congeners as effective treat-
ments for alcohol use disorders.
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